Spence Family Synovial Sarcoma Foundation shared a post on LinkedIn:
“A new profile in The Scientist revisits biochemist Cigall Kadoch and her decade-long research into the molecular drivers of synovial sarcoma.
Her team has pinpointed exactly how a fusion of just 78 amino acids hijacks the BAF complex, a chromatin regulator mutated in over 20% of all human cancers, switching on genes that should stay silenced.
These findings point toward more precise, targeted therapies for SS, with implications now reaching into other cancers as well.
Read the full article to learn more about the science shaping the future of SS treatment.”
Cigall Kadoch, Professor of Dana-Farber Cancer Institute and Scientific Founder of Foghorn Therapeutics, shared Spence Family Synovial Sarcoma Foundation’s post on LinkedIn, adding:
“Thank you so much, Spence Family Synovial Sarcoma Foundation for coming into existence and for all that you do to support pioneering work toward a cure for this devastating cancer.
Our team at Dana-Farber Cancer Institute is grateful for you.”
Other articles featuring Cigall Kadoch on OncoDaily.